Grants

Grants on Preclinical Anticancer Drug Discovery and Treatment

The research grants program administered by the Preclinical Therapeutics Grants Branch (PTGB) supports all aspects of preclinical anticancer drug discovery and treatment strategies, including drug design, selective targeting of therapeutic agents, development of new preclinical models for drug discovery, biomarker development for assessing treatment response, and understanding, preventing and overcoming drug resistance. Applications are accepted in the following drug research categories: synthesis and chemistry, natural products, screening and experimental therapeutics, pharmacology, toxicology, biochemistry and mechanism of action.

Grants on Anticancer Immunotherapeutics

The Immuno-Oncology Branch (IOB) supports extramural investigators, and NCI-funded research grants focused on all aspects of translational and preclinical development of cancer immunotherapeutics. This includes, but is not necessarily limited to, research on immune target development to various types of therapeutic modalities and combinations, such as novel immune checkpoint therapies, therapeutic vaccines, adoptive cellular therapies, immune-oncolytic therapies, preclinical testing, and IND-enabling studies.

Grants on Anticancer Biological Agents

Research on biological agents and novel animal models for cancer treatment is supported by the Biological Resources Branch (BRB). Examples include monoclonal antibodies (conjugated and unconjugated), cytokines, gene therapy using a variety of vectors, delivery of biological agents, antisense and siRNA therapy, specific animal models, and combination therapies. Although most of the grants are preclinical, some early Phase I pilot trials are also included in the BRB portfolio.

Grant applicants with applications that include clinical trials and/or studies of patient outcome are referred to the Cancer Therapy Evluation Program (CTEP).